ProKidney Corp. is a clinical-stage biotechnology company dedicated to the research, development, and commercialization of transformative cell therapies for chronic kidney disease (CKD). Headquartered in Winston-Salem, North Carolina, the company operates primarily in the United States and is focused on addressing the significant unmet medical needs of patients suffering from advanced CKD, particularly those with type 2 diabetes.
The company's core business model revolves around advancing its proprietary autologous cell therapy platform. Its lead product candidate, rilparencel (also known as REACT), is a first-in-class, patented therapy that utilizes a patient's own selected renal cells to preserve and potentially restore kidney function. Rilparencel has received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA and is currently being evaluated in a global Phase 3 clinical program (PROACT 1 and PROACT 2).
As a pre-revenue, clinical-stage company, ProKidney does not currently generate product revenue. Its operations are funded through public equity offerings, cash reserves, and its 2022 business combination with a special purpose acquisition company (SPAC). The company is actively expanding its in-house manufacturing capabilities to support late-stage clinical trials and potential future commercialization. ProKidney's competitive position is defined by its pioneering approach to regenerative medicine in nephrology, aiming to provide a disease-modifying alternative to the current standard of care, which often culminates in costly and burdensome dialysis or kidney transplantation.
